Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation

Annals of Pharmacotherapy

Volumn 41, Issue 10, 2007, Pages 1648-1659

  Lee, Jin Joo ^a,b   Lam, Masha S H ^c,e   Rosenberg, Amy ^a,d  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b FLORIDA HOSPITAL   (United States)

^c Kaiser Permanente Health Plan   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e NONE   (United States)

Author keywords

Chemotherapy; Posttransplant lymphoproliferative disorder; Rituximab; Solid organ transplantation

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; VINDESINE;

ANEMIA; ARTICLE; BLOOD PRESSURE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; DEATH; DISEASE SEVERITY; DRUG MEGADOSE; EPSTEIN BARR VIRUS; FEBRILE NEUTROPENIA; FEVER; HUMAN; INFECTION; INTESTINE PERFORATION; LEUKOPENIA; LUNG HEMORRHAGE; LYMPHOPROLIFERATIVE DISEASE; MEDLINE; MULTIPLE ORGAN FAILURE; MYALGIA; NEUTROPENIA; ORGAN TRANSPLANTATION; PAIN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PURPURA; RETROSPECTIVE STUDY; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES;

EID: 34748812533     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K175     Document Type: Article

References (35)

1. Gottschalk S, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disorders. Annu Rev Med 2005;56:29-44.
2. Sokal EM, Antunes H, Beguin C, et al. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. Transplantation 1997;64:1438-42.
3. Walker RC, Paya CV, Marshall WF, et al. Pretransplantation seronegative Epstein-Barr virus status is the primary risk factor for posttransplantation lymphoproliferative disorder in adult heart, lung, and other solid organ transplantations. J Heart Lung Transplant 1995;14:214-21.
4. Shahinian VB, Muirhead N, Jevnikar AM, et al. Epstein-Barr virus seronegativity is a risk factor for late-onset posttransplant lymphoproliferative disorder in adult renal allograft recipients. Transplantation 2003;75:851-6.
5. Dotti G, Fiocchi R, Motta T, et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000;69:827-33.
6. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation. 2001;71:1076-88.
7. Ganne V, Siddiqi N, Kamaplath B, et al. Humanized anti-CD20 monoclonal antibody (rituximab) treatment for posttransplant lymphoproliferative disorder. Clin Transplant 2003;17:417-22.
8. Jain AB, Marcos A, Pokharna R, et al. Rituximab (chimeric anti-CD20 antibody) for posttransplant lymphoproliferative disorder after solid organ transplantation in adults: long-term experience from a single center. Transplantation 2005;80:1692-8.
9. Milpied N, Vasseur B, Parquet N, et al. Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000;11:113-6.
10. Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006;107:3053-7.
11. Oertel SK, Verschuuren E, Reinke P, et al. Effect of anti-CD20 antibody rituximab in patients with post transplant lymphoproliferative disorder. Am J Transplant 2005;5:2901-6.
12. Blaes A, Peterson B, Barlett N, et al. Rituximab therapy is effective for post transplant lymphoproliferative disorders after solid organ transplantation. Cancer 2005;104:1661-7.
13. Gross TG, Bucuvalas JC, Park JR, et al. Low-dose chemotherapy for Epstein-Barr virus-positive posttransplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005;23:6481-8.
14. Fohrer C, Caillard S, Koumarianou A, et al. Long-term survival in posttransplant lymphoproliferative disorders with a dose-adjusted ACVBP regimen. Br J Haematol 2006;134:602-12.
15. Choquet S, Trappe R, Leblond V, Jager U, Davi F, Oertel S. CHOP-21 for the treatment of posttransplant lymphoproliferative disorders (PTLD) following solid organ transplantation. Haematologica 2007;92:273-4.
16. Oertel SH, Papp-Vary M, Anagnostopoulos I, Hummel MW, Jonas S, Riess HB. Salvage chemotherapy for refractory or relapsed posttransplant lymphoproliferative disorder in patients after solid organ transplantation with a combination of carboplatin and etoposide. Br J Haematol 2003;123:830-5.
17. Buell JF, Gross TG, Hanaway MJ, et al. Chemotherapy for posttransplant lymphoproliferative disorder: the Israel Penn International Transplant Tumor Registry experience. Transplant Proc 2005;37:956-7.
18. Mamzer-Bruneel MF, Lome C, Morelon E, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000;18:3622-32.
19. Trappe R, Oertel S, Choquet S, LeBlond V, Papp-Vary M, Riess H. Sequential treatment with the anti-CD 20 antibody rituximab and CHOP+GCSF chemotherapy in patients with posttransplant lymphoproliferative disorder (PTLD): first interim analysis of a multicenter phase II study (abstract). Blood (ASH Annual Meeting Abstracts) 2005;106:932
20. Orjuela M, Gross TG, Cheung YK, et al. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with posttransplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9(suppl 10 pt 2):3945S-52S.
21. Elstrom RL, Andreadis C, Aqui NA, et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006;6:569-76.
22. Taylor AL, Bowles KM, Callaghan CJ, et al. Anthracycline-based chemotherapy as first-line treatment in adults with malignant posttransplant lymphoproliferative disorder after solid organ transplantation. Transplantation 2006;82:375-81.
23. Tulpule S, Mikhaeel G, Kazmi M, et al. B cell post transplant lymphoproliferative disorder complicating solid organ transplantation (B-PTLD): a single centre review reporting 1) Results with chemo-immunotherapy (CHOP/R) and 2) the predictive ability of FDG-PET scanning to correlate with long term overall survival (abstract). Blood (ASH Annual Meeting Abstracts) 2005;106:1500.
24. Jain A, Nalesnik M, Reyes J, et al. Post transplant lymphoproliferative disorder in liver transplantation. A 20-year experience. Ann Surg 2002;236:429-37.
25. Bagot CN, Kulasekararaj A, Ramalingam S, et al. Outcome of lymphoproliferative disorder in liver transplant recipients may correlate with age at diagnosis and the use of chemotherapy: a single centre report (abstract). Blood (ASH Annual Meeting Abstracts) 2005;6:1435.
26. Benkerrou M, Jais JP, Leblond V, et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998;92:3137-47
27. Ghobrial IM, Habermann TM, Maurer MJ, et al. Prognostic analysis for survival in adult solid organ transplant recipients with posttransplantation lymphoproliferative disorders. J Clin Oncol 2005;23:7574-82.
28. Leblond V, Sutton L, Dorent R, et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995;13:961-8.
29. Muti G, Cantoni S, Oreste P, et al. Posttransplant lymphoproliferative disorders: improved outcome after clinico-pathologically tailored treatment. Haematologica 2002; 87:67-77.
30. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
31. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
32. EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Posttransplant lymphoproliferative disease (PTLD): prevention and treatment. Nephrol Dial Transplant 2002;17:31-3,35-6.
33. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-205.
34. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med 2005;142:979-95.
35. Papp-Vary M, Oertel SHK, Maschmeyer G, Riess H. Single dose per cycle pegfilgrastim successfully supports full dose CHOP-21 in patients with posttransplant lymphoproliferative disorders (PTLD) (abstract). Blood (ASH Annual Meeting Abstracts) 2004;104:4591.